Predictors and Prognostic Factors of Myasthenia Gravis Outcome

Launched by ASSIUT UNIVERSITY · Jan 26, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a condition called Myasthenia Gravis (MG), which affects the nervous system and can cause muscle weakness. The goal of the study is to better understand the different types of MG, how often they occur, and what factors might help predict how well patients respond to treatment. Researchers are particularly interested in looking at changes in muscle strength over three months and any side effects from the treatments. They also want to find out how many patients have MG that does not respond well to standard treatments.

To participate in this trial, you need to be at least 16 years old and have a clinical diagnosis of MG, which can be confirmed by specific tests. Both men and women can join. If you take part, you will undergo some tests and assessments to help researchers gather important information about the disease. The findings from this study could lead to better ways to manage MG and improve the quality of life for those affected by it.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age from 16 years and older.
• • 2. Gender: both sexes are included.
• 3. Clinical Diagnosis of MG with supporting evidence as:
• • 1. unequivocal clinical response to pyridostigmine
• • 2. decrement \>10% in repetitive nerve stimulations study (RNS).
• • 4. Willingness to sample collection, imaging study and other disease-related examinations and assessments.
• Exclusion Criteria:
• • 1. Age younger than 16 years.
• • 2. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.
• • 3. Severe systemic illness affecting life-expectancy.